Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408)

Abstract only

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 34; no. 15_suppl; p. 7507
Main Authors:	Evens, Andrew M., Hong, Fangxin, Habermann, Thomas Matthew, Advani, Ranjana H., Gascoyne, Randy D., Witzig, Thomas E., Quon, Andrew, Wagner, Lynne I., Ansell, Stephen Maxted, Petrich, Adam Matthew, Chang, Julie E., O'Brien, Timothy E., Cheema, Puneet S., Cescon, Terrence, Sturtz, Keren, Kahl, Brad S.
Format:	Journal Article
Language:	English
Published:	20-05-2016
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!